v3.26.1
Share-based compensation plan - Phantom shares plan ("PS") and Restricted Shares (Details)
 3 Months Ended
Mar. 31, 2026
BRL (R$)
shares
R$ / shares
shares
Mar. 31, 2025
BRL (R$)
Mar. 31, 2024
BRL (R$)
Dec. 31, 2025
BRL (R$)
shares
Dec. 31, 2024
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Non-current provisions for employee benefits | R$ R$ 360,657,000     R$ 332,322,000  
PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Number of other equity instruments outstanding in share-based payment arrangement 9,142,477     9,053,407  
Shares granted 972,100        
Cancelled 96,521        
Exercised (1) 786,509        
Available for completion 168,250        
Restricted stock, year one 1,999,895        
Restricted stock, year two 2,583,684        
Restricted stock, year three 3,689,847        
Restricted stock, year four 700,801        
Non-current provisions for employee benefits | R$ R$ 360,657,000     R$ 332,322,000 R$ 361,974,000
Increase Provision Share Based Payment | R$ 75,700,000 R$ 209,842,000      
Decrease Provision Share Based Payment Cancelled | R$ (2,867,000) (17,843,000)      
Decrease Provision Share Based Payment | R$ R$ (44,498,000) R$ (221,651,000)      
Phantom Share Units Psus          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Phantom Share Units Psus | R$ / shares R$ 51.88        
Restricted share units          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Number of other equity instruments outstanding in share-based payment arrangement 3,035,217     3,076,116  
Shares granted 242,383        
Exercised (1) 283,282        
Restricted stock, year one 232,651        
Restricted stock, year two 440,715        
Restricted stock, year three 235,794        
Restricted stock, year four 1,884,420        
Restricted stock, year five 241,637        
Non-current provisions for employee benefits | R$ R$ 78,728,000     R$ 80,742,000 R$ 60,226,000
Increase Provision Share Based Payment | R$ 12,597,000   R$ 45,642,000    
Decrease Provision Share Based Payment | R$ (14,611,000)   R$ (25,126,000)    
Grant Year 2021 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 64.12        
Number of other equity instruments outstanding in share-based payment arrangement 7,903     7,735  
Shares granted 168        
Available for completion 7,903        
Grant Year 2022 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 54.20        
Number of other equity instruments outstanding in share-based payment arrangement 345,288     480,184  
Shares granted 10,447        
Cancelled 221        
Exercised (1) 145,122        
Available for completion 160,347        
Restricted stock, year one 160,446        
Restricted stock, year two 24,495        
Grant Year 2023 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 48.81        
Number of other equity instruments outstanding in share-based payment arrangement 2,099,432     2,695,561  
Shares granted 58,994        
Cancelled 27,540        
Exercised (1) 627,583        
Restricted stock, year one 1,839,449        
Restricted stock, year two 259,983        
Grant Year 2023 | Restricted share units          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$       R$ 50.51  
Number of other equity instruments outstanding in share-based payment arrangement     277,249  
Shares granted 6,033        
Exercised (1) 283,282        
Grant Year 2024 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 56.58        
Number of other equity instruments outstanding in share-based payment arrangement 2,474,363     2,459,390  
Shares granted 53,332        
Cancelled 31,197        
Exercised (1) 7,162        
Restricted stock, year two 2,299,206        
Restricted stock, year three 175,157        
Grant Year 2024 | Restricted share units          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$       R$ 56.09  
Number of other equity instruments outstanding in share-based payment arrangement 2,382,333     2,331,602  
Shares granted 50,731        
Restricted stock, year one 232,651        
Restricted stock, year two 440,715        
Restricted stock, year four 1,708,967        
Grant Year 2025 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 59.65        
Number of other equity instruments outstanding in share-based payment arrangement 3,514,690     3,410,537  
Shares granted 148,358        
Cancelled 37,563        
Exercised (1) 6,642        
Restricted stock, year three 3,514,690        
Grant Year 2025 | Restricted share units          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$       R$ 60.47  
Number of other equity instruments outstanding in share-based payment arrangement 477,431     467,265  
Shares granted 10,166        
Restricted stock, year three 235,794        
Restricted stock, year five 241,637        
Grant Year 2026 | PSO          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$ R$ 50.70        
Number of other equity instruments outstanding in share-based payment arrangement 700,801        
Shares granted 700,801        
Restricted stock, year four 700,801        
Grant Year 2026 | Restricted share units          
Disclosure of terms and conditions of share-based payment arrangement [line items]          
Fair value on grant date | R$       R$ 49.70  
Number of other equity instruments outstanding in share-based payment arrangement 175,453        
Shares granted 175,453        
Restricted stock, year four 175,453